Actinium Pharmaceuticals, Inc. | April 13, 2022
Actinium Pharmaceuticals, Inc., a leader developing targeted radiotherapies for patients and Immedica Pharma AB announced that they signed a license and supply agreement for Iomab-B. It is being developed for targeted conditioning to facilitate bone marrow with topline data expected in the third quarter of 2022. For individuals with active, relapsed, or refractory acute myeloid leukemia, BMT is the only possibly curative therapy option.
"Immedica has established a strong team and impressive capabilities to commercialize specialty products in Europe, the Middle East and North Africa. Europe and the MENA countries are key commercial markets for Iomab-B, with a large addressable AML patient population and access to a strong BMT community that is highly concentrated with select leading centers performing a majority of the BMT procedures. Despite multiple drug approvals for patients with AML in recent years, curative outcomes and access to potentially curative BMT are severely lacking, particularly for patients with active, relapsed or refractory disease. We are excited to partner with Immedica to work to bring Iomab-B to patients with AML in Europe, the Middle East and North Africa who may benefit from a potentially curative transplant."
Sandesh Seth, Actinium's Chairman and CEO
"We are excited about the opportunity to make Iomab-B accessible for patients in Europe, the Middle East and North Africa. It is clear there is a large medical need for these AML patients, which we believe will be addressed by this new innovative treatment. We also look forward to deepening our collaboration with Actinium to bring the best possible support to AML treatment centers and health care professionals in Europe, the Middle East and North Africa", says Anders Edvell, CEO at Immedica.
Actinium will receive a $35 million upfront payment and will be eligible for an additional $417 million in regulatory and marketable milestone payments and royalties in the mid-twenty percent range on net sales, per the terms of the agreement. Immedica has been granted commercialization rights in Europe and, the Middle East and North Africa (MENA). Actinium will maintain all rights to Iomab-B in the United States and around the world and will be accountable for clinical and regulatory operations, as well as Iomab-B manufacturing.